Cell>Point Overview
- Year Founded
-
2001
- Status
-
Out of Business
- Employees
-
51
- Latest Deal Type
-
Out of Business
Cell>Point General Information
Description
Developer of intra-nuclear molecular imaging and therapeutic compounds designed to treat diabetes and cardiovascular diseases. The company's compounds focus on chelation-based metabolic imaging and intranuclear target-specific therapy for oncology and cardiology, including stroke, neuroendocrine, and ischemic-based diseases, enabling healthcare professionals to treat their patients effectively and cure them.
Contact Information
Website
www.celltheranostics.comCorporate Office
- 7120 East Orchard Road
- Suite 350
- Centennial, CO 80111
- United States
Corporate Office
- 7120 East Orchard Road
- Suite 350
- Centennial, CO 80111
- United States
Cell>Point Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 30-May-2026 | Completed | Out of Business | |||
| 7. Later Stage VC | 17-Jun-2021 | Cancelled | Generating Revenue | |||
| 6. Later Stage VC | 16-Jun-2021 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 16-Jan-2018 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 24-May-2012 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 26-Apr-2011 | Completed | Startup | |||
| 2. Angel (individual) | 01-Jan-2011 | $32.4M | $43M | Completed | Startup | |
| 1. Angel (individual) | 26-Mar-2010 | $10.6M | $10.6M | Completed | Startup |
Cell>Point Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cell>Point Patents
Cell>Point Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20110085969-A1 | Chelator-targeting ligand conjugates for cardiovascular imaging | Inactive | 09-Oct-2009 | ||
| US-20170281806-A1 | Chelator-targeting ligand conjugates for cardiovascular imaging | Inactive | 09-Oct-2009 | ||
| WO-2011044377-A2 | Chelator-targeting ligand conjugates for cardiovascular imaging | Inactive | 09-Oct-2009 | ||
| WO-2011044377-A3 | Chelator-targeting ligand conjugates for cardiovascular imaging | Inactive | 09-Oct-2009 | ||
| US-20080107598-A1 | Conjugating a chelator, ethylenedicysteine to a targeting ligand, glucosamine, deoxyglucose, metronidazole, annexin v, guanine or lhrh; and a metal ion of 99mtc, 68ga, 188re or 187re | Active | 05-Oct-2006 | A61K47/50 |
Cell>Point Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cell>Point FAQs
-
When was Cell>Point founded?
Cell>Point was founded in 2001.
-
Where is Cell>Point headquartered?
Cell>Point is headquartered in Centennial, CO.
-
What is the size of Cell>Point?
Cell>Point has 51 total employees.
-
What industry is Cell>Point in?
Cell>Point’s primary industry is Biotechnology.
-
Is Cell>Point a private or public company?
Cell>Point is a Private company.
-
What is Cell>Point’s current revenue?
The current revenue for Cell>Point is .
-
How much funding has Cell>Point raised over time?
Cell>Point has raised $66.6M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
